Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics, Inc. (AVTX)
:AVTX
AVTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.39 - $16.00
Previous CloseN/A
Volume10.82K
Average Volume (3M)235.33K
Market Cap
$123.11M
Enterprise Value-$56.56M
Total Cash (Recent Filing)$125.05M
Total Debt (Recent Filing)$801.00K
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 06, 2025EPS Estimate
-1.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding13,152,356
10 Day Avg. Volume452,545
30 Day Avg. Volume235,331
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)136.95
P/FCF Ratio-1.23
Enterprise Value/Market Cap-0.46
Enterprise Value/Revenue-128.26
Enterprise Value/Gross Profit-78.02
Enterprise Value/Ebitda1.13
Forecast
1Y Price Target
$28.98Price Target Upside209.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Analyst UpgradeAvalo Therapeutics has received an analyst upgrade to Buy, with a 12-month price target of $15, highlighting confidence in the company's future performance.
Financial StabilityAvalo's cash position of $113.3M is expected to fund operations into 2028, providing a runway through key value inflection points.
Market PotentialHS remains a large, under-penetrated market with high-growth potential, where there is adequate room for multiple advanced therapies to coexist and be commercially successful.
Bears Say
Clinical Development RisksRisks include potential delays to AVTX-009 clinical development and failure to achieve approval.
Competitor BenchmarksRisks include delays to AVTX-009 clinical development and negative clinical data with AVTX-009, with particular attention to competitor HiSCR75 benchmarks.
Financial PerformanceAvalo recorded a 2Q25 net loss of $1.92 per share, which was higher than the estimated net loss of $1.23 per share.
Avalo Therapeutics News
AVTX FAQ
What was Avalo Therapeutics, Inc.’s price range in the past 12 months?
Avalo Therapeutics, Inc. lowest stock price was $3.39 and its highest was $16.00 in the past 12 months.
What is Avalo Therapeutics, Inc.’s market cap?
Avalo Therapeutics, Inc.’s market cap is $123.11M.
When is Avalo Therapeutics, Inc.’s upcoming earnings report date?
Avalo Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 84 days.
How were Avalo Therapeutics, Inc.’s earnings last quarter?
Avalo Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$1.92 earnings per share for the quarter, missing the consensus estimate of -$1.402 by -$0.518.
Is Avalo Therapeutics, Inc. overvalued?
According to Wall Street analysts Avalo Therapeutics, Inc.’s price is currently Undervalued.
Does Avalo Therapeutics, Inc. pay dividends?
Avalo Therapeutics, Inc. does not currently pay dividends.
What is Avalo Therapeutics, Inc.’s EPS estimate?
Avalo Therapeutics, Inc.’s EPS estimate is -1.64.
How many shares outstanding does Avalo Therapeutics, Inc. have?
Avalo Therapeutics, Inc. has 13,152,356 shares outstanding.
What happened to Avalo Therapeutics, Inc.’s price movement after its last earnings report?
Avalo Therapeutics, Inc. reported an EPS of -$1.92 in its last earnings report, missing expectations of -$1.402. Following the earnings report the stock price went up 0.481%.
Which hedge fund is a major shareholder of Avalo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AVTX
Avalo Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.98 (209.62% Upside)
$28.98 (209.62% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 520.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.45%
12-Months-Change
Fundamentals
Return on Equity
-90.25%
Trailing 12-Months
Asset Growth
16.87%
Trailing 12-Months
Company Description
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
AVTX Stock 12 Month Forecast
Average Price Target
$28.98
▲(209.62% Upside)